Baker Brothers Advisors - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 79 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2013. The put-call ratio across all filers is 44.37 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2018$7,871,000
-54.2%
979,016
-57.5%
0.06%
-59.6%
Q1 2018$17,204,000
-8.2%
2,306,184
-26.8%
0.15%
-9.9%
Q4 2017$18,747,000
-19.2%
3,150,8080.0%0.16%
-13.8%
Q3 2017$23,190,000
+8.4%
3,150,8080.0%0.19%
+0.5%
Q2 2017$21,394,000
-28.1%
3,150,8080.0%0.19%
-23.0%
Q1 2017$29,744,000
+9.3%
3,150,8080.0%0.24%
-9.0%
Q4 2016$27,223,000
+17.8%
3,150,808
-13.7%
0.27%
+27.1%
Q3 2016$23,110,000
+37.9%
3,650,808
-8.0%
0.21%
+19.3%
Q2 2016$16,754,000
-11.7%
3,970,250
-8.7%
0.18%
-12.0%
Q1 2016$18,970,000
-28.9%
4,350,8080.0%0.20%
-9.5%
Q4 2015$26,670,000
+7.2%
4,350,8080.0%0.22%
-3.9%
Q3 2015$24,887,000
-23.3%
4,350,8080.0%0.23%
-19.3%
Q2 2015$32,457,000
+24.7%
4,350,8080.0%0.28%
+31.9%
Q1 2015$26,018,000
-22.7%
4,350,808
-2.2%
0.22%
-37.0%
Q4 2014$33,640,000
+45.7%
4,449,7970.0%0.34%
+17.9%
Q3 2014$23,094,000
+20.4%
4,449,7970.0%0.29%
+23.8%
Q2 2014$19,179,000
+5.4%
4,449,7970.0%0.24%
+1.7%
Q1 2014$18,200,000
-18.7%
4,449,797
+5.9%
0.23%
-26.7%
Q4 2013$22,386,000
+6.2%
4,200,0000.0%0.32%
+5.0%
Q3 2013$21,084,000
+12.6%
4,200,0000.0%0.30%
-19.1%
Q2 2013$18,732,0004,200,0000.37%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q2 2013
NameSharesValueWeighting ↓
ARDSLEY ADVISORY PARTNERS LP 1,255,000$5,823,0001.12%
Phocas Financial Corp. 1,146,292$5,319,0000.54%
Worth Venture Partners, LLC 138,357$641,0000.36%
RICE HALL JAMES & ASSOCIATES, LLC 2,293,179$10,640,0000.34%
Monashee Investment Management LLC 240,000$1,114,0000.26%
BKS ADVISORS, LLC 118,587$550,0000.22%
PINNACLE ASSOCIATES LTD 1,418,391$6,581,0000.15%
FARALLON CAPITAL MANAGEMENT LLC 4,200,820$19,492,0000.15%
Fosun International Ltd 472,580$2,174,0000.14%
CARILLON TOWER ADVISERS, INC. 3,948,024$18,318,0000.13%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders